CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Project Number | pCODR 10141 |
|---|---|
| Brand Name | Revlimid |
| Generic Name | Lenalidomide |
| Strength | 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg |
| Tumour Type | Myeloma |
| Indication | Multiple Myeloma |
| Funding Request | The combination of lenalidomide, bortezomib, and low-dose dexamethasone, for the treatment of newly diagnosed multiple myeloma patients in whom stem cell transplantation is not intended |
| Review Status | Notification to Implement Issued |
| Pre Noc Submission | No |
| NOC Date | N/A |
| Manufacturer | Celgene Inc. |
| Sponsor | Celgene Inc. |
| Submission Date (Target Date) | December 21, 2018 |
| Submission Deemed Complete | January 14, 2019 |
| Submission Type | New Indication |
| Prioritization Requested | |
| Stakeholder Input Deadline ‡ | January 14, 2019 |
| Check-point meeting | March 5, 2019 |
| pERC Meeting | May 16, 2019 |
| Initial Recommendation Issued | May 31, 2019 |
| Feedback Deadline ‡ | June 14, 2019 |
| Final Recommendation Issued | June 19, 2019 |
| Notification to Implement Issued | July 5, 2019 |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
